Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor Mobilization in SCD
NCT03226691Phase 1Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plerixafor in sickle cell disease (SCD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events at 1 day. Started Jul 2017; status: completed.
02
Drugs
plerixafor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03226691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226691.